Welcome to our dedicated page for Rallybio SEC filings (Ticker: RLYB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rallybio Corporation (RLYB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, clinical-stage biotechnology company focused on severe and rare diseases, Rallybio uses its Forms 10-K, 10-Q, and 8-K to report financial performance, pipeline developments, and material corporate events.
Rallybio’s filings include quarterly and annual reports that detail collaboration and license revenue, research and development expenses, general and administrative expenses, net income or loss, and cash, cash equivalents, and marketable securities. These reports also describe the status of key programs such as RLYB116, a differentiated C5 inhibitor in a confirmatory PK/PD Phase 1 study, and preclinical assets like RLYB332 for diseases of iron overload. Disclosures about discontinued programs, such as RLYB212 for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), appear in these documents and related press releases.
Current Reports on Form 8-K provide timely updates on material events, including quarterly financial results, the sale of Rallybio’s interest in the ENPP1 inhibitor program REV102 to Recursion Pharmaceuticals, and Nasdaq listing matters. An August 2025 8-K, for example, describes the transfer of Rallybio’s listing to the Nasdaq Capital Market and the additional compliance period granted to regain the minimum bid price requirement.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand changes in Rallybio’s financial position, pipeline priorities, and corporate transactions. Users can review real-time updates from EDGAR, examine historical 10-K and 10-Q reports, and track 8-K disclosures related to financing, collaborations, and listing compliance, all in one place.
Rallybio Corporation (NASDAQ: RLYB) has divested its 50 % ownership in RE Ventures I, LLC (the ENPP1 joint venture) to Recursion Pharmaceuticals for immediate and potential future consideration.
- Initial consideration: Recursion issued 1,457,952 Class A shares (VWAP $5.1442) valued at $7.5 million on 8 July 2025.
- Make-whole mechanism: If Rallybio’s net proceeds from selling the Initial Shares differ from $7.5 million, the party benefiting must true-up the difference in cash.
- Contingent equity: Upon achievement of specified development milestones for the ENPP1 compound, Rallybio may receive additional shares worth up to $12.5 million, with the same make-whole feature.
- Milestone & royalty stream: The agreement grants Rallybio undisclosed cash milestone payments and low-single-digit royalties on future net sales of ENPP1-related products.
- Following the sale, the ENPP1 JV becomes an indirect wholly-owned subsidiary of Recursion; Rallybio relinquishes all equity interest.
The transaction strengthens Rallybio’s liquidity with $7.5 million in equity that can be monetised, de-risks ongoing ENPP1 development costs, and leaves upside through contingent consideration and royalties. However, future value now depends on milestones achieved by Recursion, and Rallybio forgoes direct participation in the JV’s long-term upside.
Rallybio (NASDAQ:RLYB) filed an 8-K announcing a new employment agreement with Chief Medical Officer Steven Ryder, M.D.
Key terms
- Base salary: $531,227
- Annual target bonus: 40% of salary
- Initial one-year term with automatic one-year renewals
- Standard severance: 12 months salary, prior bonus and up to 12 months COBRA
- Change-in-control severance: 1.5× salary + target bonus, 18 months COBRA and full vesting of time-based equity
Severance requires a release of claims; a 12-month non-compete and non-solicitation applies. No other operational or financial updates were disclosed.